Medical Condition News

RSS

Eli Lilly's Cymbalta receives FDA approval

The U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the maintenance treatment of generalized anxiety disorder (GAD) in adults, announced Eli Lilly and Company (NYSE: LLY).

30 Nov 2009

MHI team performs catheter implantation of the new Amptlazer Cardiac Plug prosthesis

A multidisciplinary team from the Montreal Heart Institute (MHI) performed its first catheter implantation of a new prosthesis (Amptlazer(R) Cardiac Plug) closing the appendage of the left atrium of the heart, which will have the effect of preventing the formation of blood clots and avoiding open-heart surgery. This is excellent news for patients suffering from atrial fibrillation, the most common form of cardiac arrhythmia, affecting at least 5% of Canadians over the age of 70.

30 Nov 2009

Micromet to present new results from its blinatumomab study at the ASH meeting

Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will present new results from its clinical studies with blinatumomab at the 51st annual meeting of the American Society of Hematology from December 5-8, 2009 in New Orleans, Louisiana.

30 Nov 2009

ALS research collaboration receives philanthropic funding

Three prominent philanthropic organizations – The Angel Fund, The ALS Therapy Alliance and Project ALS -- dedicated to finding a treatment for amyotrophic lateral sclerosis (ALS) have financed a new collaboration between one of the world’s leading ALS researchers and RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi).

30 Nov 2009

Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial

Spectrum Pharmaceuticals today announced that one of the two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target, having enrolled approximately 800 patients with non-invasive bladder cancer. The second Phase 3 clinical trial of apaziquone is expected to complete enrollment by the end of the year.

30 Nov 2009

Presentations at Tuesday's RSNA conference

A new study from Cincinnati Children's Hospital Medical Center reports that beverage can stay-tabs pose a potential ingestion risk. In the 1970s, U.S. manufacturers switched to the stay-tab design after safety concerns about pull-tabs. The new study found 19 cases of stay-tab ingestion at a single institution, mainly among teenagers.

30 Nov 2009

Centene announces new program to educate children on the importance of active and healthy lifestyle

Centene Corporation today announced the creation of a program called Kids' Club, aimed at educating its child members on a variety of health topics. Centene's health plans are reaching out directly to children with newsletters, contests and other innovative events, such as readings with the author of "The Adventures of Thumbs Up Johnnie(TM)."

30 Nov 2009

Minerva Biotechnologies grants Clarient exclusive commercializing rights to its MUC1 diagnostic test

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that privately held, Waltham, MA-based Minerva Biotechnologies has granted it the exclusive right to develop and commercialize a test that identifies the MUC1* protein, a biomarker researchers believe may be implicated in the spread of many cancers, including breast cancer.

30 Nov 2009

Sentinelle Medical's Aegis Navigation MRI and ultrasound imaging system showcased at RSNA 2009

Sentinelle Medical Inc., a leading manufacturer of MRI coils and advanced visualization software is demonstrating a number of innovative new works-in-progress, including MRI and ultrasound co-registration offering at RSNA 2009.

30 Nov 2009

CDS announces second Disability Intensive Course on cerebral palsy

The College of Direct Support (CDS), an internet-based curriculum for direct support professionals and managed in partnership by MC Strategies/Elsevier and the University of Minnesota's Research and Training Center, announced today that its second Disability Intensive Course (DIC) on "Cerebral Palsy" is now available for administrators and learners to use as part of the online curriculum.

30 Nov 2009

"Skin" to aid hearing

An apparatus that converts sound to vibrations makes it possible for individuals who are deaf and blind or severely hearing impaired to perceive and recognize sounds with their skin. The method, which can also be adapted for infants, has been developed by engineering researcher Parivash Ranjbar, who is submitting his findings in a new dissertation at örebro University in Sweden.

30 Nov 2009

HPS offers recommendations against potential risks caused by radon in indoor environment

Radon is a colorless and odorless radioactive gas that is produced by the radioactive decay of radium. Radium is a product of uranium decay and is found in trace amounts naturally in nearly all rocks, soils, and groundwater as well as building materials, plants, animals, and the human body.

30 Nov 2009

Cell Therapeutics' platinum-based anti-tumor compounds demonstrate stronger anti-tumor potency

Cell Therapeutics, Inc. (CTI) announced today that its new class of platinum-based anti-tumor compounds, termed bis-platinates, demonstrated a stronger anti-tumor potency and activity compared to currently available platinum-based compounds as well as the ability to overcome cisplatin-resistance in cancer cell lines.

30 Nov 2009

Charity urges government to stop under 18s from using sunbeds

Tomorrow Scotland takes steps to protect children from sunbeds by banning under 18s from using them and ensuring adults are fully informed of the risks, Cancer Research UK wants Westminster to bring the rest of the UK up to Scottish standards.

30 Nov 2009

Prevalence of osteoarthritis continues to rise; OA expenses nearly 100% higher for women than men

Osteoarthritis (OA), a highly prevalent disease, raised aggregate annual medical care expenditures in the U.S. by $185.5 billion according to researchers from Stony Brook University. Insurers footed $149.4 billion of the total medical spend and out-of-pocket (OOP) expenditures were $36.1 billion (2007 dollars). Results of the cost analysis study are published in the December issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.

30 Nov 2009

Interventions by parent mentors can effectively reduce wheezing and asthma attacks in children

UT Southwestern Medical Center researchers have found that informed adults can help families stave off complications associated with asthma. The findings, available online and in the December issue of Pediatrics, suggest that interventions by parent mentors - caregivers of asthmatic children who have received specialized topical training - can effectively reduce wheezing, asthma attacks, emergency room visits and missed adult workdays.

30 Nov 2009

Mobile phones with special software now offer accurate diagnosis of acute appendicitis

Radiologists can accurately diagnose acute appendicitis from a remote location with the use of a handheld device or mobile phone equipped with special software, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

30 Nov 2009

Early intervention for young children with autism improves IQ, communication and social interaction

A novel early intervention program for very young children with autism - some as young as 18 months - is effective for improving IQ, language ability, and social interaction, a comprehensive new study has found.

30 Nov 2009

Elastography decreases breast biopsies and maps tumors more precisely

Elastography is an effective, convenient technique that, when added to breast ultrasound, helps distinguish cancerous breast lesions from benign results, according to an ongoing study presented today at the annual meeting of the Radiological Society of North America (RSNA).

30 Nov 2009

High levels of physical activity may damage knees and increase risk for osteoarthritis

Middle-aged men and women who engage in high levels of physical activity may be unknowingly causing damage to their knees and increasing their risk for osteoarthritis, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

30 Nov 2009

Medical Condition News

Eli Lilly's Cymbalta receives FDA approval

MHI team performs catheter implantation of the new Amptlazer Cardiac Plug prosthesis

Micromet to present new results from its blinatumomab study at the ASH meeting

ALS research collaboration receives philanthropic funding

Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial

Presentations at Tuesday's RSNA conference

Centene announces new program to educate children on the importance of active and healthy lifestyle

Minerva Biotechnologies grants Clarient exclusive commercializing rights to its MUC1 diagnostic test

Sentinelle Medical's Aegis Navigation MRI and ultrasound imaging system showcased at RSNA 2009

CDS announces second Disability Intensive Course on cerebral palsy

"Skin" to aid hearing

HPS offers recommendations against potential risks caused by radon in indoor environment

Cell Therapeutics' platinum-based anti-tumor compounds demonstrate stronger anti-tumor potency

Charity urges government to stop under 18s from using sunbeds

Prevalence of osteoarthritis continues to rise; OA expenses nearly 100% higher for women than men

Interventions by parent mentors can effectively reduce wheezing and asthma attacks in children

Mobile phones with special software now offer accurate diagnosis of acute appendicitis

Early intervention for young children with autism improves IQ, communication and social interaction

Elastography decreases breast biopsies and maps tumors more precisely

High levels of physical activity may damage knees and increase risk for osteoarthritis

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News